By Mariam Sunny Jan 26 (Reuters) - Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy slowed disease progression and showed sustained benefit in patients' ability to control and ...

Sarepta’s blockbuster gene therapy has come under scrutiny following a string of patient deaths.

ST. LOUIS — On a cloudy morning in Forest Park, families gathered not just to take steps together but to take them for each other. The Muscular Dystrophy Association's 2025 Muscle Walk on May 4 drew ...

"Muscular dystrophy can take many things from me, but it will not take away my happiness, nor will it take away my faith." ...

A Sarepta Therapeutics gene therapy that failed its confirmatory test has now converted its accelerated FDA approval into a traditional one, expanding use of the treatment to a wider group of Duchenne ...

The father-of-two, Rich Clift, 38, will take on the 100km walk (spanning two days 16 - 17 May 2026), along with three others including brothers-in-law, Ashley ...

Disability advocate TaLisha Gryzb is a mother of four living with muscular dystrophy who educates viewers about her ...

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. Sarepta reported the ...